Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IceCure Medical (ICCM) Cash & Equivalents (2020 - 2025)

IceCure Medical (ICCM) has disclosed Cash & Equivalents for 5 consecutive years, with $7.6 million as the latest value for Q4 2024.

  • On a quarterly basis, Cash & Equivalents fell 28.19% to $7.6 million in Q4 2024 year-over-year; TTM through Dec 2024 was $7.6 million, a 28.19% decrease, with the full-year FY2024 number at $7.6 million, down 28.19% from a year prior.
  • Cash & Equivalents was $7.6 million for Q4 2024 at IceCure Medical, down from $10.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $25.6 million in Q4 2021 to a low of $3.5 million in Q4 2020.
  • A 5-year average of $14.2 million and a median of $10.5 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: soared 631.61% in 2021, then tumbled 55.48% in 2023.
  • IceCure Medical's Cash & Equivalents stood at $3.5 million in 2020, then skyrocketed by 631.61% to $25.6 million in 2021, then fell by 7.66% to $23.7 million in 2022, then tumbled by 55.48% to $10.5 million in 2023, then decreased by 28.19% to $7.6 million in 2024.
  • Per Business Quant, the three most recent readings for ICCM's Cash & Equivalents are $7.6 million (Q4 2024), $10.5 million (Q4 2023), and $23.7 million (Q4 2022).